Data Gluttony? Why Big Pharma is Addicted to 5.9 Million Useless Clinical Trial Datapoints

The lead site coordinator stared at the tablet, then at the patient, then back at the tablet. They were forty minutes into a routine Phase III oncology visit, and they hadn’t even administered the investigational product yet. The patient was exhausted, having just completed the fourth Quality of Life questionnaire of the morning—questions that, statistically, would likely never influence the primary endpoint of the study.

This is the quiet, daily failure of clinical research. We have entered the era of Protocol Ossification.

While the industry publicly champions pragmatic trials and patient-centricity, the internal machinery of Big Pharma has become a self-preserving logic loop that prioritizes data volume over clinical value. We aren’t just collecting data anymore; we are hoarding it in a digital basement, terrified that throwing anything away might upset a regulator who is actually asking us to clean house.

The 5.9 Million Datapoint Anchor

The scale of this data gluttony is now quantified. A Phase III protocol today gathers an average of 5.9 million datapoints, a staggering 67% increase since 2020. According to the Tufts Center for the Study of Drug Development (CSDD), this volume has grown at an 11% annual rate. If this trajectory continues, by 2030, a single trial will produce enough noise to drown out any signal of clinical efficacy.

The disruption isn’t just in the volume; it’s in the waste. Recent collaborative research between Tufts CSDD and 15 TransCelerate member companies reveals that nearly one-third of all procedures and datapoints collected are classified as non-core (exploratory) or non-essential. In non-oncology Phase III trials, the combined proportion of waste reaches nearly 40%. We are effectively asking sites and patients to perform a ghost trial alongside the real one—a secondary, invisible study that adds no regulatory value but consumes up to 30% of the site’s total capacity.

The Regulatory Green Light (That No One is Using)

The most biting irony is that the regulators have already given us the keys to the exit. The finalized ICH E6(R3) and E8(R1) guidelines are not just suggestions; they are a mandate to avoid unnecessary complexity, procedures, and data collection.

The FDA’s Project Pragmatica and the Center for Clinical Trial Innovation (C3TI) were designed specifically to strip protocols down to their scientific essence. Yet, as I’ve argued before, these remain industry buzzwords. Most drug approvals still rely on traditional randomized controlled trials because sponsors hesitate to embrace the models. They treat real-world data (RWD) as a supplementary nice-to-have rather than the primary source of evidence it could be.

The industry applauds itself for advancing trial design, but when it comes to execution, we’re still stuck in a cycle of overpromising and underdelivering. Without clearer guidance and more consistent regulatory acceptance, sponsors remain hesitant to embrace pragmatic trial designs fully.

Why Big Pharma Won’t Let Go: The Anatomy of Inertia

If the path to simplicity is so clear, why is the industry doubling down on complexity? The why is rooted in institutional anxiety and a fragmented decision-making process.

1. The Just-in-Case Safety Net: Protocols are the culmination of dozens of internal meetings and inputs from external collaborators. In this environment, it is easier to say “yes” to an extra biomarker than to say “no” to a senior stakeholder’s pet project. The fear of undervaluation or a missing data point during a regulatory query drives a hoarding mentality.
2. The Ghost of Future Research: Nearly half (46%) of non-core procedures in Phase II are conducted for exploratory and future use purposes. We are essentially taxing today’s trials and today’s patients to pay for hypothetical research that may never happen.
3. The Questionnaire Paradox: Nowhere is this ossification more visible than in Patient-Reported Outcomes. Under the banner of hearing the patient’s voice, we have burdened them with an unsustainable number of assessments. Questionnaires have the highest proportion of non-core and non-essential data, totaling 55.4% of the data they generate.

The Psychology of Complexity: Career Insurance and Additive Bias

The failure to simplify isn’t a lack of clinical intelligence; it is a byproduct of Loss Aversion and Additive Bias. Research published in Nature suggests that the human brain systematically overlooks subtractive changes when solving problems, defaulting instead to adding new elements. In large bureaucratic structures, this biological tic is amplified by Compliance Theater—the ritualistic performance of procedures to serve the internal hierarchy rather than the regulatory requirement.

For a mid-level clinical lead, data volume is career insurance. According to Harvard Business Review’s analysis of organizational learning, complexity often serves as a defensive wall against personal accountability. If a drug fails its primary endpoint, a hoarded data set provides the necessary noise to find a post-hoc hint of a signal that justifies the lead’s role and the program’s budget.

Furthermore, Big Pharma suffers from what Clayton Christensen famously described as the Innovator’s Dilemma. Because these organizations are built to optimize high-margin, low-risk blockbuster cycles, they view pragmatic or minimalist trials as a threat to their established quality-control rituals. To the corporate mind, a streamlined protocol looks like a cheap protocol, and cheap is conflated with risky.

This manifests in the protocol design room as Decision By Silo. Every functional head—from Clinical Operations to Market Access—approaches the trial as a finite window of opportunity. They treat the participant not as a patient, but as a data-commodity to be mined for their specific silo’s KPIs. The result is a protocol that is scientifically sound on paper but operationally impossible in practice. As research indicates, as much as 17% of Phase III data is generated by non-essential procedures—assessments conducted solely to satisfy internal consensus, not clinical necessity.

A New Strategic Mandate: The Zero-Based Protocol

To disrupt this, we need to move beyond optimization and toward Zero-Based Protocol Design. In this model, a protocol starts with zero procedures. Every single datapoint must be defended by a direct link to the primary or key secondary endpoint.

The data supporting this shift is undeniable. Research from Tufts CSDD demonstrates that protocols with a higher relative number of endpoints and procedures have longer mean enrollment durations and a higher incidence of protocol deviations. Conversely, streamlining is the only way to reverse the trend where clinical trial speed and efficiency have steadily worsened over the past two decades.

In a Zero-Based environment:

• Essential Only: Every procedure is evaluated against its minimal frequency required to demonstrate a clinical outcome. Currently, between 7% and 13% of Phase II and III procedures are performed more times than scientifically necessary.
• Decoupling Innovation from Burden: Exploratory endpoints, which currently account for nearly 35% of non-core procedures in Phase III, are shifted to optional sub-studies. This prevents the taxation of the general trial population for data that won’t impact the primary approval.
• Site and Participant Relief: By eliminating the non-essential and non-core procedures, sponsors can reduce participant and site burden by as much as 30%. This isn’t just a nice-to-have metric; it is the difference between a trial that completes on time and one that requires a mid-stream rescue.

The industry talks about integrating RWD, yet concerns about standardization continue to delay its application. We need to stop treating every nice-to-have biomarker as a regulatory requirement. The data shows that the more we collect, the more we jeopardize study quality. Higher data volume leads to higher error rates and lower participant retention. Streamlining isn’t just about saving costs—it’s about preserving the integrity of the science.

The Human Mandate: Beyond the Data-Commodity

Ultimately, this isn’t just an operational crisis—it is a human one. When we talk about 5.9 million datapoints, we are talking about millions of minutes stolen from people who are often fighting for their lives.

The clinical trial participant has been demoted from a partner in discovery to a line item in an exploratory budget. Every non-essential blood draw is a needle prick, a bruise, and an extra hour in a cold waiting room. Every redundant questionnaire is a logistical tax on a life already strained by illness. We have framed patient-centricity as asking the patient more questions, when true respect for the patient would be asking them fewer.

The recruitment crisis isn’t a mystery; it’s a natural response to a research model that treats participant time as an infinite resource. If we want to restore progress, we must stop treating the patient as a data-commodity to be mined and start treating their time as the finite, sacred asset it actually is.

The Strategic Takeaway: The growth of clinical trial data isn’t a sign of scientific progress; it’s a sign of institutional anxiety. The first company to truly embrace minimalist trials—aligned with ICH E6(R3)—won’t just save money; they will win the war for patient and site recruitment by offering the one thing Big Pharma has forgotten to provide: respect for the human at the center of the storm. The ossification of clinical research is a choice. It’s time to choose a different path.